AMRNMEDIUM SIGNALFINANCIAL10-K

AMRN achieved a significant operational turnaround with operating cash flow swinging from -$31M to +$6.7M while revenue grew 39% and losses narrowed substantially.

The company demonstrates improving financial health with strong revenue growth, dramatically reduced SG&A expenses, and a shift to positive operating cash flow indicating better working capital management. The substantial debt reduction of 38% combined with higher cash balances suggests improved liquidity and financial stability.

Comparing 2026-03-02 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

AMRN shows a comprehensive financial improvement with revenue growing 39% to $181M driving gross profit up 49%, while management successfully reduced SG&A expenses by 25% and cut debt by 38%. The most significant achievement was the swing from negative $31M to positive $6.7M operating cash flow, indicating the company has reached an inflection point in cash generation. Overall, the financial picture signals a business moving toward profitability with stronger operational efficiency and improved balance sheet strength.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+121.7%
-$31.0M→$6.7M

Operating cash flow surged 121.7% — exceptional cash generation, highest quality earnings signal.

Capital Expenditure
Cash Flow
-89.8%
$2.5M→$252K

Capex reduced 89.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Income
P&L
+52.8%
-$82.2M→-$38.8M

Net income grew 52.8% — bottom-line growth signals improving overall business health.

Gross Profit
P&L
+48.5%
$81.4M→$120.9M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Operating Income
P&L
+45.3%
-$91.8M→-$50.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Revenue
P&L
+39.2%
$130.1M→$181.1M

Strong top-line growth of 39.2% — accelerating demand or successful expansion into new markets.

Total Debt
Balance Sheet
-37.6%
$79.7M→$49.7M

Debt reduced 37.6% — deleveraging strengthens balance sheet and reduces financial risk.

SG&A Expense
P&L
-24.5%
$152.3M→$115.0M

SG&A reduced 24.5% — improved cost efficiency or headcount reduction improving operating margins.

Inventory
Balance Sheet
+18%
$166.0M→$195.9M

Inventory built 18% — monitor whether demand supports this build or if write-downs may follow.

Cash & Equivalents
Balance Sheet
+11.3%
$121.0M→$134.7M

Cash grew 11.3% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-03-12
ADDED
416,079,145 Ordinary Shares, 50 pence par value per share, were outstanding as of February 20, 2026, including 20,364,324 Ordinary Shares held as American Depositary Shares (ADSs), each representing 20 Ordinary Share.
Market For Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 62 Item 6.
FDA, in July 2012 for use as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe ( 500 mg/dL) hypertriglyceridemia, or the MARINE indication.
On March 26, 2021, the European Commission, or EC, approved the marketing authorization application for VASCEPA, under the brand name VAZKEPA , hereinafter along with VASCEPA, collectively referred to as VASCEPA, in the European Union, or EU, to reduce the risk of cardiovascular events in high-risk statin-treated adult patients who have elevated triglycerides ( 150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk event.
On April 22, 2021, we announced that the Medicines and Healthcare Products Regulatory Agency, or MHRA, approved VAZKEPA in England, Scotland and Wales to reduce cardiovascular risk.
+7 more — sign up free →
REMOVED
414,186,296 shares were outstanding as of February 28, 2025, including 405,383,488 shares held as American Depositary Shares (ADSs), each representing one Ordinary Share, 50 pence par value per share, and 8,802,808 Ordinary Shares.
Market For Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 60 Item 7.
Our primary office for our European market access team is located at berbauung Metalli, Gotthardstrasse 2, Zug CH-6300, Switzerland.
For purposes of this Annual Report, our ordinary shares may also be referred to as common shares or common stock.
FDA, for use as an adjunct to diet to reduce triglyceride, or TG, levels in adult patients with severe ( 500 mg/dL) hypertriglyceridemia, or the MARINE indication and we commercially launched in 2013.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →